Product Description
Autologous CD19-CD22 CAR-T cells. (Sourced from: https://classic.clinicaltrials.gov/ct2/show/NCT04034446)
Mechanisms of Action: CAR-T, CD19, CD22
Novel Mechanism: Yes
Modality: Autologous CAR-T
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Heyuan Biotechnology (Tianjin) Co., Ltd.
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: B-Cell Leukemia|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Lymphoma, B-Cell|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Lymphoma, Non-Hodgkin|Acute Lymphoid Leukemia
Phase 1: Lymphoma, B-Cell|Lymphoma, Non-Hodgkin|Acute Lymphoid Leukemia|B-Cell Leukemia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
CTR20232686 |
CTR20232686 | P1 |
Not yet recruiting |
Lymphoma, B-Cell|Lymphoma, Non-Hodgkin |
None |
2025-04-29 |
Patient Enrollment|Treatments|Trial Status |
|
CTR20232688 |
CTR20232688 | P1 |
Not yet recruiting |
Acute Lymphoid Leukemia|B-Cell Leukemia |
None |
2025-04-29 |
Patient Enrollment|Treatments|Trial Status |
|
NCT06009107 |
B-ALL | P2 |
Withdrawn |
Precursor Cell Lymphoblastic Leukemia-Lymphoma|B-Cell Leukemia|Lymphoma, B-Cell|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Acute Lymphoid Leukemia |
2026-12-30 |
12% |
2025-08-13 |
Patient Enrollment|Primary Endpoints|Treatments|Trial Status |
NCT06005649 |
HY004102 | P2 |
Withdrawn |
Lymphoma, Non-Hodgkin|Lymphoma, B-Cell |
2026-06-01 |
12% |
2025-08-13 |
Patient Enrollment|Primary Endpoints|Start Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|